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 1 
ABSTRACT 
 
Prophylactic cancer vaccination presents novel opportunities to improve the health and well-
being of populations. Since the approval of a cervical cancer vaccine against human 
papillomavirus (HPV) in 2006, only three states have passed legislation adding it to their school-
entry schedules of required vaccinations. Despite ample evidence of its safety and efficacy, the 
vaccine remains controversial, and national vaccination rates among both girls and boys remain 
low. Risk for HPV-related cancers varies by population, and Appalachian Kentucky has among 
the highest HPV-related morbidity and mortality in the nation. Annual attempts to pass HPV 
vaccine legislation in Kentucky have so far failed in the absence of directly targeted quantitative 
data on the risks and rewards of action vs. inaction. We herein present the first known impact 
assessment of an HPV vaccine school entry requirement for the state of Kentucky, using a 
transmission-dynamic model to simulate vaccine scenarios in the context of Kentucky’s high 
HPV disease burden and unique population characteristics. Our findings suggest that over the 
lifetime of those first vaccinated after passage, such a policy could prevent approximately 18 
thousand cancers and 3 thousand deaths; preserve 18 thousand life-years and more than 34 
thousand quality-adjusted life years; and save as much as 1.3 billion USD in the state of 
Kentucky.  
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ACRONYMS AND ABBREVIATIONS 
 
13RS-HB358 – 2013 Regular Session, House Bill 358 
4vHPV – Quadrivalent HPV 
9vHPV – Nonavalent HPV 
AAFP – American Academy of Family Physicians 
AAP – American Academy of Pediatrics 
ACIP – Advisory Committee on Immunization Practices 
ACOG – American College of Obstetricians and Gynecologists 
ACP – American College of Physicians 
ASTHO – Association of State and Territorial Health Officials 
CAST – Centre for Applied Health Services Research and Technology 
CDC – Centers for Disease Control and Prevention 
CPSTF – Community Preventive Services Task Force 
DCC – Distant Metastatic Cervical Cancer 
FDA – Food and Drug Administration 
HHS – Department of Health and Human Services 
HPV – Human Papillomavirus 
HPV-MOK – Human Papillomavirus Model of Kentucky 
ICER – Incremental Cost-Effectiveness Ratio 
JORRP – Juvenile Onset Recurrent Respiratory Papillomatosis 
LCC – Locally Invasive Cervical Cancer 
NGO – Non-governmental Organization 
OECD – Organization for Economic Co-operation and Development 
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PCE – Personal Consumption Expenditure 
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QALY – Quality Adjusted Life Year 
RCC – Regionally Invasive Cervical Cancer 
SIS – Susceptible-Infectious-Susceptible 
TDAP – Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine  
USA – United States of America 
USD – United States Dollar 
WHO – World Health Organization 
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INTRODUCTION 
 
The possibility of cancer prevention by vaccination has tantalized physicians, scientists, 
and the public health community for over a century, at least since Coley’s attempts to use 
bacterial immunotherapy for cancer treatment laid the foundation for the use of Bacillus 
Calmette-Guérin to prevent the recurrence of superficial bladder cancer.1 Later, vaccination 
against Hepatitis B to prevent hepatocellular carcinoma was based on Blumberg’s Nobel Prize-
winning work demonstrating the causal link between hepatitis B and HCC during the 1960s and 
’70s.1 
But these developments were only harbingers of the idea’s potential, recurrent bladder 
and hepatitis B-related liver cancers being relatively rare. The biggest breakthrough in cancer 
vaccination to date emerged during the early 1990s from clinical trials testing the safety and 
efficacy of vaccines against two human papillomavirus (HPV) types implicated in cervical 
cancer1 - the second most common cancer among women in highly developed countries, and a 
leading female malignancy and cause of death among middle-aged women in ‘developing’ 
nations.2 The Food and Drug Administration (FDA) subsequently approved a quadrivalent HPV 
(4vHPV) vaccine (Gardasil™, Merck & Co., Inc.)3 covering types 6, 11, 16, and 18 for the 
prevention of genital warts and cervical cancers in 2006,1 making it the first licensed vaccine 
against a common sexually transmitted infection.4 Together, these four HPV types etiologically 
account for approximately 68% of squamous cell cervical cancers, 83% of adenocarcinomas of 
the cervix, 90% of anogenital condylomas,5 and a large fraction of all other anogenital and 
oropharyngeal dysplasias and malignancies in both males and females.5,6 A nonavalent (9vHPV) 
vaccine was approved by the FDA in 2015, which adds the high-risk types 31, 33, 45, 52, and 58, 
and has the potential to prevent the large majority of all health-relevant HPV infections.7 
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Though the vast majority of countries set vaccine policy at the national level, the United 
States (USA) does not. Instead, each state, district, or territory retains authority to set public 
health policy, including vaccine policy. Nevertheless, the USA has a long history of mandatory 
vaccination, with conditions for school entry dating back to the early 1800s.8 Today, all 50 of her 
states have school-entry vaccine laws, but only three states or districts – Washington, D.C., 
Virginia, and Rhode Island – have so far added the HPV vaccine to their respective school entry 
schedules, despite strong endorsement of school entry policies to increase vaccine schedule 
adherence from the Community Preventive Services Task Force (CPSTF),9 the Association of 
State and Territorial Health Officials (ASTHO),10 and public health agencies throughout the 
USA. The Centers for Disease Control and Prevention (CDC) HPV vaccine recommendations 
are for both females and males, but so far only Rhode Island’s legislation has included males in 
its mandate.11 
The reasons for failure of state lawmakers to move HPV vaccine legislation forward are 
complex. Here, it is sufficient to note that this failure is not due to a lack of evidence for, or 
informed support of, the effectiveness of school entry requirements to increase vaccine uptake, 
population coverage, and disease reduction. According to the CPSTF’s systematic review of 
seventeen scientific studies examining the effectiveness of state or local vaccination 
requirements on changes in vaccination rates, the median change was an increase of 18%.12 
Other studies reviewed in their report found significant reductions in vaccine-preventable disease 
rates in states with school entry laws requiring that vaccine.9,12 
Kentucky was among the first states to propose HPV vaccine legislation immediately 
following the FDA’s approval and the CDC’s recommendation release in 2006. But here, as 
elsewhere in the country, the legislation faced a large pushback that continues today. Kentucky-
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specific quantitative data is one critical factor missing from the HPV vaccine policy discussion in 
Kentucky’s capital, Frankfort. Until recently, the epidemiology of HPV in Kentucky was 
presumed to match that estimated for the USA’s general population. But data published in 2017 
identified prevalence rates in Appalachian Kentucky 2-5 times higher than national age-matched 
averages,13 consistent with the high incidence of HPV-related cancers at-large in Kentucky, and 
the even higher rates observed in the Appalachian region of the state.  
New information creates new possibilities. New targeted prevalence data can now be 
used to inform population-specific modeling of the potential impact of legislation adding the 
HPV vaccine to the school entry schedule in Kentucky. This paper presents one such quantitative 
estimate of impact, and thus fills a critical gap necessary for rational, evidence-based health 
policy discussion in the Commonwealth. 
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BACKGROUND 
Papillomaviruses are a ubiquitous family of non-enveloped DNA viruses infecting 
virtually all amniotes, including humans.14 More than 150 human papillomavirus (HPV) types 
have been sequenced and are divided into five evolutionary groups15 found to infect epithelial 
mucosa, cutaneous membranes, or both. Clinically relevant HPV types are categorized by their 
known associations with human cancers, as either high-risk or low-risk serotypes. 
HPV is the most common sexually transmitted infection in the world, with an estimated 6 
million or more new infections annually in the United States alone.8 We now know that HPV is 
the necessary cause of cervical16 and other cancers,17 being found in 99.7% of all cervical cancer 
tissue specimens, low- and high-grade squamous intraepithelial lesions, and abnormal 
Papanicolaou (Pap) test results.18 Yet, as recently as 1970, the HPV virus was assumed to be a 
monotypic, medically irrelevant, spontaneously cleared nuisance.19 Only during the decades 
following the advent and development of recombinant DNA technology20 did a fuller picture 
emerge of the diversity of its biology and disease-causing capacity.4,21 
HPV exposure most commonly, but not necessarily, results from sexual contact. Though 
most infections resolve over time, persistent infections with oncogenic types have been shown to 
cause cervical cancer17 – the second most common cancer among women worldwide – and plays 
a central role in subsets of several other invasive cancers, including those of the vagina, vulva,22 
penis,23 anus,24 oral cavity and pharynx.25 Other diseases associated with HPV types include 
precancerous lesions of the cervix (cervical intraepithelial neoplasias),26 oral papillomas, genital 
warts, respiratory papillomatosis, and in rare cases, epidermodysplasia verruciformis among the 
immunocompromised.27 
 
 
 9 
Estimates of global deaths attributable to cervical cancer alone28 approximate estimates 
of global all-cause maternal mortality29 – the subject of far more international attention than the 
former. As much as 88% of these deaths occur in low-income countries.28 Projection of cervical 
cancer mortality through 2030 is bleaker, with half a million annual deaths expected. 
Furthermore, rates in sub-Saharan Africa are expected to double,30 even though the vast majority 
could be prevented by existing vaccine technology. Overall, the direct annual medical costs 
attributable to HPV in the USA during the period of 2004-07 was estimated to have been 
between 4 and 14 billion USD.31 
HPV Vaccine Policy 
During the first decade of the HPV vaccine era, national programs have been successfully 
implemented, either preemptive or subsequent to WHO recommendations, in countries such as 
Australia,32 Belgium,33 Canada,34 Denmark,35,36 France,37 Greece,38 Iceland,39 Israel,40 Italy,41 
Japan,42 New Zealand,43 Norway,44 Portugal,45 Singapore,46 Spain,47 Sweden,48 and the United 
Kingdom of Great Britain and Northern Ireland.49 Further, many middle- and low-income, 
recently developed or developing countries such as Argentina,50 Brazil,51–53 Brunei,54 Mexico,55 
Slovenia and Macedonia,56 and Uganda57, among others, have begun national vaccination 
campaigns. As of 2016, a total of 86 countries had added the HPV vaccine to their national 
vaccination schedules.58 However, international vaccine pricing practices favor high-income 
countries, for whom the sum health and economic benefits from the vaccine are greatest,59 which 
furthers the irony of low policy and programmatic adoption in the USA. 
There is no national vaccination program in the USA. The federal government is highly 
limited in its role within vaccine policy and delivery to one of setting agendas, guidelines, and 
recommendations. Instead, each state regulates vaccination within its borders largely through 
 
 
 10 
laws that require students to prove adherence to a medically-informed, but politically-derived, 
vaccination schedule before allowed entry to schools, and in some cases, daycares and colleges. 
The Advisory Committee on Immunization Practices (ACIP),60 which informs the official 
policies of both the CDC and the Department of Health and Human Services (HHS), 
recommends both males and females ages 11 or 12 receive the HPV vaccine. It further 
recommends that unvaccinated females between 13-26 and males 13-21 years of age also receive 
the full series.61 Many other federal and state health or disease agencies have added HPV 
vaccination for both girls and boys before sexual debut to their priority agendas, including the 
President’s Cancer Panel,62 the National Foundation for Infectious Diseases,63 and the National 
Cancer Institute.64 National medical non-governmental organizations (NGOs) and advocacy 
groups, too, have published supportive positions on universal HPV vaccination, including the 
American College of Obstetricians and Gynecologists (ACOG),65 the American Academy of 
Family Physicians (AAFP),66 the American Academy of Pediatrics (AAP),67 and the American 
College of Physicians (ACP).68 
For years, HPV vaccine uptake in the USA had remained one of the lowest among the 
Organization for Economic Co-operation and Development (OECD) nations, due, in part, to the 
fractured and inconsistent nature of healthcare policy and delivery in the US system. But 
recently, the USA has made progress in relation to its peers: In 2015, 52.2% (+/- 1.8) of girls and 
39% (+/- 1.7) of boys between ages 13-17 had received at least 2 HPV vaccine doses, though 
rates varied significantly by region, and state,69 placing the USA more squarely near the mean 
for high-income countries (48.5% [CI: 38.6 - 59.3]).70 
HPV in Kentucky 
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In arguing for a transformative framework for global health justice, and in reference to 
impoverished and developing nations, Gostin argued that health inequalities represent an 
enduring and consequential global health challenge.71 Yet one need not travel beyond US borders 
to identify dramatic examples of “the inequitable distribution of disease and early death”.71  
The Appalachian cultural region, which includes parts of 13 eastern USA states and 
approximately 25 million people, is characterized by poor socioeconomic, health, and 
environmental indicators,72 especially in the central Appalachian states of West Virginia, Ohio, 
and Kentucky.73 Appalachian Kentucky, in a state recognized for its high HPV-related cancer 
burden74 and low HPV vaccination rates,75 has among the highest HPV-related cancer death rates 
– for both males and females – in the United States.76 In addition to the social determinants that 
shape health status in Appalachian Kentucky, specific risk factors for the development of HPV-
related cancers are common is this population. High smoking rates, risky sexual behavior,77 
lower screening and vaccination rates, high comorbidities,78 and even fatalistic beliefs79 may all 
be contributing factors. 
The HPV-related cancer incidence rate in non-Appalachian Kentucky has been assessed 
at 22.0 and 21.3 per hundred thousand for females and males, respectively. The rate for 
Appalachian Kentucky is even higher, at 24.6 and 21.9, female and male.76 Another study 
calculated the relative risk of Appalachian Kentuckians for cervical cancer as 1.23 that of non-
Appalachian Kentuckians.80 For some counties of Appalachia, like Harlan County, KY, the rate 
is nearly three times (21.1) the national rate per hundred thousand (8.1; all values age-adjusted to 
the 2000 US Standard Million Population).76 Mortality rates from HPV-related cancers in 
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Kentucky are similarly high: 3.2 for cervical cancer (but 4.8 for African American Kentuckians), 
0.8 for vaginal and vulvar cancers, and 3.0 for oral and pharyngeal cancers (per hundred 
thousand; age-adjusted).81 Therefore, any study of Kentucky health policy must consider the 
disparate distribution of disease burden within the state, and therefore the inevitably disparate 
distribution of health policy effects. 
Until now, Kentucky-specific HPV infection prevalence data has not been available. 
However, data collected between 2013 and 2014 by Crosby and Vanderpool, et al.82 has recently 
been analyzed for type-specific prevalence and risk factors among a co-screening aged cohort of 
398 women in Appalachian Kentucky.13 Any-type HPV prevalence was found to be 55.6%; 
33.3% for high-risk, and 45.5% for low-risk types. Fifty percent of those infected were infected 
with at least one nonavalent (9vHPV; Gardasil 9™) vaccine type, and 70.5% of infected women 
had multiple simultaneous infections. For women in the youngest age group in the study, aged 
30-34, the any-type prevalence was 58.3%. This is an important point, because in most studies of 
HPV epidemiology to date, the highest prevalence rates have been found among women under 
30 years of age, and usually under 25. If similar ratios hold in Kentucky, then the risk pool into 
which young Appalachian Kentuckians are sexually debuting may carry a significantly higher 
viral load than reflected by these already high prevalence rates, and much higher than the age-
matched national averages. 
HPV Vaccination in Kentucky 
Nationally, approximately 40% of girls aged 13-17 had received the (then) full 3-dose 
HPV vaccine series in 2014.83 The rate among boys was much lower – nearly half, at 21.6% - but 
still an increase of more than 8% over the previous year.83,84 Though the burden of HPV 
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infection and disease is higher in Kentucky than in most of the US, HPV vaccine uptake has 
lagged, especially among males. According to 2014 data collected and published by the CDC, 
the adolescent HPV vaccine completion rate in Kentucky was 37.5 and 13.3% for females and 
males, respectively.83 Promisingly, since 2016, CDC guidelines now recommend a 2-dose 
schedule for girls and boys under 14 years of age, which is likely to improve compliance rates 
going forward, though the degree of its effect is not yet known.85 
HPV Vaccine Policy in Kentucky 
HPV vaccine legislation has been debated in Kentucky since the 2006 legislative session, 
when bills 143, 345, and 327 were introduced in the House. Since then, at least six other bills 
have been proposed. During the 2013 regular session, house bill 358 (13RS-HB358), which 
proposed to amend KRS 214.034 to require the HPV vaccine for females (ages 9-16) and males 
(ages 10-16) entering 6th grade, and to require parental withholding of consent be kept on file by 
schools, died in the Kentucky Senate following house passage, 54-40.86 13RS-HB358 is the 
closest to evidence-based HPV legislation Kentucky has come, and has therefore been used to 
define this study’s simulation parameters for HPV legislation in Kentucky. 
The questions addressed by this study, of whether and to what degree Kentucky’s current 
vaccination rates may contribute to a herd immunity; or may reduce the overall prevalence of 
HPV infection in the Commonwealth; or may impact the health outcomes of current cohorts 
compared to those preceding and unvaccinated; or may compare to future cohorts with even 
greater vaccine coverage – should legislation like 13RS-HB358, which proposed to add the HPV 
vaccine to the state’s school entry schedule of required vaccines, pass in Kentucky – are both 
timely and consequential. 
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METHODS 
Study Goal, Objectives, Aims 
Our goal was to generate novel, population-specific quantitative data and to analyze its 
practical implications for vaccine policy in the Commonwealth of Kentucky, USA.  
The main objectives of this study were twofold. First, to broadly assess the HPV vaccine 
landscape, an overview of the virus’ biology, pathology, and epidemiology has been included, as 
well as a brief account of the efforts so far put forth to develop, test, distribute, and legislate the 
HPV vaccine (see Background section, above).  
Second, to address the central question of the impact of HPV vaccine legislation (such as 
13RS-HB358) in Kentucky, we have developed a quantitative computer model of HPV infection, 
transmission, clearance, and sequelae capable of simulating multiple vaccine policy scenarios. 
To facilitate evidence-based health policy decision-making relating to the HPV vaccine, we 
focused on the outcomes of three relevant scenarios:  
1. No vaccination: a vaccination rate of zero was used as a control for comparison of scenarios 
2 and 3 to a pre-vaccine baseline. In this way, both the progress so far, as well as the health 
and economic impacts of vaccine legislation, could be estimated. 
2. Current vaccination: the current HPV vaccination rates83 were used to simulate Kentucky’s 
current trajectory and expected benefits should rates remain at current levels. 
3. Required vaccination: the HPV vaccination rate was matched to the average compliance rates 
for Kentucky’s currently scheduled 6th-grade entry vaccines (the TDAP booster and the 
meningococcal vaccine; 2014-16) to simulate passage of legislation similar to 13RS-HB358. 
The simulation model herein described was adapted from a previously developed and 
published model87 originally tailored to Danish36 and Irish populations.88 Parameters of the model 
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were calibrated to reflect Kentucky’s unique incidence, prevalence, risk factors, and population 
characteristics. Using an agent-based transmission approach, the model simulates infection and 
disease dynamics over time. At simulation endpoint, model agent states were interpreted as 
population outcomes, translated to measures of health impact, or extrapolated to address 
questions of economic impact.  
Using this policy impact model for 13RS-HB358, several specific aims were addressed. 
The primary aim was to determine and compare the epidemiological patterns of infection (in 
terms of type-specific prevalences) and health outcomes (in terms of cancers prevented and lives 
saved, measured from baseline) of scenarios 2 and 3.  
Next, we calculated the health impact of 13RS-HB358 in terms of the differences in life 
years and quality-adjusted life years (QALYs) gained over baseline between the two vaccine 
scenarios.  
Finally, to assess the long-term direct economic impact of 13RS-HB358, we calculated the 
society-payer perspective costs associated with vaccination against future healthcare 
expenditures averted as an incremental cost-effectiveness ratio (ICER), or cost per QALY, using 
the oft-cited benchmark of 50,000 USD as the comparative measure of utility. 
The Model: Policy Simulations 
With the recent arrival of cervical cancer vaccines, modeling studies have become 
increasingly common and complex, with researchers and agencies alike eager to inform historic 
policy developments in countries all over the world. The models used vary in step with the 
complexity of the variables involved, creating a large number of distinguishing characteristics 
and a variety of model strengths to consider. 
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To determine which model type would be best suited to this study’s goals and objectives, 
many different characteristics were evaluated: time horizons and discounting; 
comprehensiveness of included diseases and their natural histories; effectiveness and duration of 
vaccine-induced protections; herd and cross immunities (i.e., protections to those not directly 
vaccinated, and protections to HPV types not specifically included in the vaccine, respectively); 
quality of life; costs and payer perspectives; uncertainty;89 and the flexibility to accommodate the 
sex behaviors, age distribution, relevant risk factors, type-specific prevalences, and disease 
progression rates unique to the population of interest.90 
Model Type and Targets 
In the end, a stochastic, susceptible-infectious-susceptible (SIS), agent-based dynamic 
model, originally developed by Jens Olsen with the Centre for Applied Health Services Research 
and Technology Assessment (CAST), University of Southern Denmark, was selected. 
Commissioned by the Danish government to inform its national HPV vaccine policy, the model 
simulated the transmission biology of HPV types 6, 11, 16, and 18 under the condition of several 
assumptions, including 100% vaccine effectiveness and lifetime duration of immunity. Herd 
immunity is accounted for by the dynamic modelling environment, but it does not recognize 
cross-immunity to other HPV types. The stochastic agent-based model allows for fine calibration 
of the sex behaviors, age-specific prevalences, and disease progression rates to the study 
population. The model uses the NETLOGO multi-agent modeling environment (version 5.3.1; 
http://ccl.northwestern.edu/netlogo/). For this study, the model was significantly expanded to 
include all viral types covered by the 9-valent HPV vaccine, and adapted to Kentucky’s unique 
population to address the following scenarios (Table 1): 
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1. No Vaccination: the cumulative outcomes given no vaccination as a baseline measure against 
which to compare each of the experimental scenarios 
2. Current Vaccination: the cumulative outcomes given 9vHPV vaccination rates of 37.5 and 
13.3 percent among 11-year-old girls and boys, respectively  
3. Required Vaccination: the cumulative outcomes given 9vHPV vaccination of 83.125 
percent91 of 11-year-old boys and girls 
 
Table 1. Vaccination coverage of 11-year-olds for HPV-MOK simulation scenarios. 
Scenario Vaccination coverage, girls Vaccination coverage, boys 
1. No vaccination (pre-vaccine era) 0% 0% 
2. Current vaccination (present day)83 37.5% 13.3% 
3. Required vaccination (13RS-HB358)91 83.125% 83.125% 
 
 
 
Disease Model Characteristics 
The new model, forthwith referred to as the HPV Model of Kentucky (HPV-MOK), 
simulates the infection dynamics of the high-risk types 16, 18, 31, 33, 45, 52, and 58, as covered 
by the nonavalent (9vHPV) vaccine, Gardasil 9. These types have been shown to account for 
most cervical, vulvar and vaginal, anal, oropharyngeal, and penile precancers and cancers, 
including 90% of all cervical cancers.61 In addition, the model simulates low-risk types 6 and 11, 
also covered by the 9vHPV vaccine, which are believed to cause at least 90% of all anogenital 
warts,92 and at least 90% of juvenile onset recurrent respiratory papillomatosis (JORRP).93 HPV-
MOK was also programmed to simulate Kentucky’s unique epidemiology of HPV-related 
cervical diseases (Table 2). 
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Table 2. HPV-MOK pre-simulation calibration parameters, targets, and values. 
Parameter Prevalence Target*, % Value achieved, % 
HPV6 2.66 2.30 
HPV11 0.16 1.12 
HPV16 5.03 5.13 
HPV18 1.87 2.08 
HVP31 2.38 2.52 
HPV33 1.13 1.55 
HPV45 1.87 2.03 
HPV52 3.33 3.27 
HPV58 1.59 1.62 
Parameter Incidence Target, % Value achieved, % 
CIN1 0.2994 0.32 
Cervical Cancer, incidence 0.01581 0.014 
Parameter Value  Source  
Cervical cancer screening rate 81.3; Present KY screening rate CDC BRFSS95 
Age at death 76.26; Present KY life expectancy US Census data 
Initial age distribution Present Kentucky age distribution US Census data 
Initial gender distribution Present Kentucky gender distribution US Census data 
 
*Estimated KY prevalences from national (NHANES96) and regional (Appalachian Kentucky13) data, adjusted by geographic population 
distribution and age. 
 
 
Model Assumptions and Variables 
With any model, the advantages of simplifications are weighed against their effects on 
the validity and reliability of predictions. In this case, several simplifications of transmission and 
clearance dynamics were assumed: 
• Heterosexual population 
• HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58 only 
• Persistent HPV infections with an exponential distribution of duration 
• No natural immunity 
• No cross protection 
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• No vaccine failure and no waning efficacy 
• No risk factors beyond sexual behavior 
Because non-cervical HPV infection and disease course progression are poorly 
understood, it is difficult to realistically model the underlying biological processes of these 
conditions. To simplify the model while maintaining coherence with real-world measures, the 
incidences of HPV-related non-cervical disease were assumed to decrease proportionately with 
that of cervical cancer, which HPV-MOK models directly and in detail. Population variables 
include viral transmission and clearance dynamics, disease progression and regression 
probabilities, and similar universally-applicable probabilities. Other variables are agent-specific, 
distinguishing this class of dynamic modeling from static procedures (see Table 3 for a full list of 
simulation variables). 
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Table 3. HPV-MOK simulation variables. 
Variable  Value  Source  
HPV → CIN1 0.009; Probability per month Elbasha et al.97 
CIN1 → HPV/clear (regress) 0.329; Probability per year 
CIN1 → CIN2 0.136; Probability per year Values determined from model 
calibration CIN2 → CIN1 (regress) 0.133; Probability per year 
CIN2 → CIN3 0.10; Probability per year 
CIN3 → CIN2 (regress) 0.03; Probability per year 
CIN3 → LCC → RCC → DCC 0.10 per progression; Probability per year 
HPV 6/11 → genital warts 0.075; Probability per year 
Risk of HPV 6/11/16 
infection 
0.35; probability per intercourse Elbasha et al.97 
Risk of HPV 18, 31, 33, 45, 
52, or 58 infection 
Proportional to HPV 16 based on measured 
prevalence ratios 
Modified compared to the HPV 16 
risk to reflect their lower 
prevalences 
Concurrent partners 0, 1, or 2, uniform/block distribution Estimate 
Duration of relationship (in 
months) 
Dependent on age: the older, the longer 
duration (Y = abs random-normal (0.8·age – 
12) (age/0.5)·12). 
Estimate 
Frequency of sexual 
intercourse 
Random-gamma distribution with a mean of 
9.48 per month; SD 9.95 
Burchell et al.98 
Vaccination status 0 or 1   
Duration of infections: 
     HPV 6 
     HPV 11 
     HPV 16 
     HPV 18 
     HPV 31 
     HPV 33 
     HPV 45 
     HPV 52 
     HPV 58 
Exponential distribution means: 
     11.32 
     9.50 
     14.6 
     11.26 
     11.518 
     11.3 
     11.51 
     12.40 
     11.14 
Values independently defined 
during model calibration 
Duration of genital warts Random-gamma 6 1.5 
 
 
 
 
Following the “expert consensus” described by Ultsch et al. for dynamic model 
simulations,89 the simulations were allowed to run until epidemiological equilibrium was 
achieved to assure that all positive and negative effects of the experimental variable (vaccination 
rate) would be captured across policy scenarios. The model was repeatedly run for 250 simulated 
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years, its output analyzed, and the type-specific durations of infection were calibrated until the 
model achieved a viral prevalence steady-state consistent with Kentucky’s real-world rates 
(Table 2). Type-specific prevalences were calculated from both national and regional published 
epidemiological data. NHANES, a nationally representative health dataset with HPV prevalence 
measures from the pre-vaccine era was used as proxy for non-Appalachia Kentucky. Though 
limited, existing data from Appalachian Kentucky suggests regional HPV prevalences 
significantly higher than national averages, so proportionately weighted composite age-adjusted 
prevalences drawn from both sources were used to define the HPV-MOK seed population. A 
model limitation was identified during calibration involving the low prevalence target for HPV 
11. The virus type could not be stabilized at such a low rate in the relatively small simulated 
populations. However, by adjusting the probability of condyloma formation, the condyloma 
prevalence rate target was still matched.   
Next, the model was again repeatedly run for 250 years in order to calibrate the pathology 
progression and regression variables to reproduce known Kentucky cervical cancer incidence at 
steady-state rates (Table 3). 
Model Outputs 
Once calibrated, the scenarios were run in 4 replicates, each with an initial population of 
25,000 nodes. A post-analysis time horizon of 66 years was adopted to accommodate the full 
lifespan of the first vaccinated cohorts. Model outputs for each scenario were collected, replicate 
data were combined, and all data were transformed and analyzed using Google Sheets (Google 
Inc, 2017, Mountain View, CA), a web-based spreadsheet software.  
The 9vHPV type-specific prevalences were calculated and are reported as population 
proportions for each scenario. The HPV-related disease incidences and mortality rates across 
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scenarios were assessed, adjusted (Table 4), and are reported for scenarios 2 and 3 as cancers 
prevented and lives saved per hundred thousand persons without discounting. 
 
 
Table 4. HPV-MOK post-simulation pathology parameter adjustment targets. 
Pathology  9vHPV proportion Incidence*,81 Mortality*,81  Mean age at diagnosis 
Cervical Cancer 0.9099 16.7 3.2 49100 
Vulvar Cancer 0.63101 10.1 0.6 68102 
Vaginal Cancer 0.73101 1.9 0.3 60103 
Anal Cancer 0.95104 2.4 0.2 61105 
Oropharyngeal Cancers 0.66101 13.3 3.0 53106 
Penile Cancer 0.57101 2.0 0.2 68107 
Condyloma 1.0108 194.5109 
N/A 
JORRP 1.0110 4.3111 (per 100k <14yo) 
 
*Annual rate, per 100 thousand population 
 
 
The QALYs gained in scenarios 2 and 3 were calculated by comparing the reduction in 
morbidity and mortality in each from those in the baseline control scenario (see Table 5 for 
QALY weights by age and disease burden). Life-years gained were determined from differences 
in the age distributions for cancer deaths versus the general population, multiplied by the annual 
HPV-related cancer mortality rates in each scenario. Future life-years and QALYs were 
discounted at the same rate as future monetary costs and savings. 
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Table 5. HPV-MOK life-year quality adjustments and unit costs per variable. 
Variable  QALY Modifier87,112 Unit Cost*; PV, USD 
Age Group 
     00-08 
     09-14 
     15-19 
     20-24 
     25-29 
     30-34 
     35-39 
     40-44 
     45-49 
     50-54 
     55-59 
     60-64 
     65-69 
     70-74 
     75-79 
 
1.0 
1.0 
0.92880 
0.92880 
0.92880 
0.92365 
0.90475 
0.89405 
0.89005 
0.86560 
0.87060 
0.86495 
0.84495 
0.83785 
0.81330 
N/A 
CIN1 0.91 2,412.84113  
CIN2 0.87 6,215.17114,115 
CIN3 0.87 7,056.49114,115 
Locally invasive Cervical Cancer (LCC) 0.76 45,291.20114,115 
Regionally invasive Cervical Cancer (RCC) 0.67 48,516.54114,115 
Distant metastasis Cervical Cancer (DCC) 0.48 77,715.20114,115 
Vulvar Cancer 0.68 30,802.80116 
Vaginal Cancer 0.68 35,342.15116 
Anal Cancer 0.68 53,414.27116 
Oropharyngeal Cancers 0.68 77,769.26106 
Penile Cancer 0.68 25,802.67116 
Condyloma 0.91 991.84116 
JORRP 0.69 143,411.45116 
Vaccination 
     Vaccine (x2) 
     Administration (x2) 
Mild reaction (probability: 0.00105) 
     Severe reaction (probability 0.00009) 
 
 
 
0.001117 
0.076118 
476.74  
204.8760 
33.00119 
65.42120,121 
4,768.18120,121 
Screening 
     Office visit 
     Cytology 
     HPV DNA test 
     Patient time 
 165.94122 
30.96 
37.15 
68.11 
29.72 
 
*Medical costs of treatment, estimated cost of vaccination, or estimated cost of cervical cancer screening per incident. 
PV: Present value. USD: United States dollars. 
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Following Gold et al.’s recommendations,123 HPV-MOK uses a societal perspective that 
includes costs – vaccination costs, cancer screening costs, and future healthcare sector costs of 
treatment for HPV-associated diseases – and benefits, regardless of payer or beneficiary. The 
direct policy costs were limited to the financial cost of the 2 dose HPV vaccine series, set at 
204.87 USD per dose per person,124 plus 33.00 USD for each vaccine administration,119 and any 
medical costs associated with rare vaccine reactions (Table 5).120 These are reported in USD 
after adjustment for inflation and discounting. 
The nature of prevention regularly puts the costs of intervention near the present, with 
subsequent benefits delayed into the far future. This distinctive characteristic of prevention 
renders decisions based on evaluations of relative value, whether by legislators considering 
policy or an individual considering personal choices, vulnerable to the irrational biases inherent 
to human psychology. The HPV-MOK uses a 3.0% discount rate for all future costs (whether 
incurred or averted) and benefits to account for the time value of money, but does not further 
discount for time preference.125 
Future averted costs of treatments for genital warts, JORRP, CIN1-3 and atypia, cervical 
cancer, genital cancers, and head & neck cancers were estimated from the available literature to 
reflect present value (Table 5) and are described in USDs. Results from simulations were 
discounted and adjusted for inflation. Because the cost of healthcare is expected to continue to 
outpace the general economic inflation rate for the foreseeable future, both a healthcare inflation 
factor and a consumer price index inflation factor were incorporated in our estimates (Table 6). 
A broader projection of total economic costs relating to the modeled policy, including the 
opportunity, legislative, and implementation costs (recurrent and operational) was not included 
in this analysis.  
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Table 6. Economic and population terms. 
Variable  Value, % Reference 
Personal Consumption Expenditure (PCE) 
price index average inflation (2006-15) 
1.62 Bureau of Economic Analysis, US Department of 
Commerce National Accounts (NIPA) data archive126 
CMS NHEA healthcare inflation rate, 
averaged projections (2017-26) 
5.49 Centers for Medicare & Medicaid Services, Office of the 
Actuary National Health Expenditure Account127 
Discount rate for both costs and effects 3.0 Second Panel on Cost-Effectiveness in Health and 
Medicine128 
Annual population growth, Kentucky 0.42 Kentucky State Data Center Projections of Population 
and Households129 
 
 
The World Health Organization (WHO) recommends that cost-effectiveness be 
considered in HPV vaccine policy decisions.130 We therefore incorporated the adjusted monetary 
values for costs and benefits into calculations of incremental cost (defined as direct policy costs 
minus future costs averted, in USD) per QALY gained (without equity weightings)131 to assess 
the potential cost-effectiveness of legislation similar to 13RS-HB358 in Kentucky.   
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RESULTS 
Aim 1: Patterns of Infection and Health Outcomes 
HPV type-specific prevalences varied across scenarios (Figure 1). While prevalences 
were fairly stable through time in Scenario 1 (steady-state), both vaccination scenarios resulted 
in a steep decline in all HPV types soon after vaccine introduction (at time point zero). In 
Scenario 2, several of the modelled types were eventually eliminated from the population despite 
relatively low vaccination coverage, suggesting a strong herd effect. Also in Scenario 2, types 16 
and 52 achieved a new steady-state prevalence in the population approximately 25 years after 
vaccine introduction (Figure 1-b). In contrast, Scenario 3 saw all 9 types eliminated from the 
population within about 13 years of vaccine introduction (Figure 1-c). 
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Figure 1. 9vHPV type-specific prevalences among scenarios 1 – no vaccination (a), 2 – current 
vaccination rates (b), and 3 – required vaccination under proposed policy (c).  
 
 
 
 
 The cervical disease burden associated with the 9 HPV types studied was, in the pre-
vaccine world modelled by Scenario 1, stable and comparable to real-world historical incidence 
rates observed for Kentucky (Figure 2-a and Table 2). Upon vaccine introduction in both 
Scenarios 2 and 3, 9vHPV-related cervical disease incidences dropped precipitously, with 
condylomas eventually being eradicated from the simulated populations. Scenario 2 saw an 
average drop in CIN1 incidence by nearly three-quarters and achieved low steady-state rates of 
all cervical precancerous pathologies within 25 years (Figure 2-b). Meanwhile, new 
precancerous lesions were eliminated completely in Scenario 3 within just 15 years (Figure 2-c). 
a 
b 
c 
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Cervical cancer, attributable to older uncleared infections, followed a slower decline in both 
scenarios, and was eventually eliminated from scenario 3 once the pre-vaccine era population 
had expired (the last cancer case occurred in year 64 after vaccine introduction; Figure 2-c).   
 
 
 
Figure 2. 9vHPV-related cervical disease among scenarios 1 – no vaccination (a), 2 – current 
vaccination rates (b), and 3 – required vaccination under proposed policy (c). 
 
 
 
 
 
 
 
a 
b 
c 
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Non-cervical cancers were not directly modelled but were assumed to track 
proportionally with cervical cancer. Additionally, incidences of JORRP were assumed to decline 
proportionally with the declining prevalences of HPV types 6 and 11 in the vaccination 
scenarios. Figure 3 shows the relative annual incidences of non-cervical 9vHPV-related cancers 
calculated from simulation outputs. In both vaccination scenarios, incidences of non-cervical 
cancers fell, and were virtually eliminated over the full time horizon of Scenario 3 (Figure 3-c).  
 
 
 
 
Figure 3. 9vHPV-related non-cervical cancer incidence rates among scenarios 1 – no vaccination 
(a), 2 – current vaccination rates (b), and 3 – required vaccination under proposed policy (c). 
 
 
 
 
a 
b 
c 
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 Table 7 shows the annual incidence averages of 9vHPV-related diseases per hundred 
thousand population. Again, only cervical diseases, including condylomas, were directly 
simulated by the HPV-MOK model; other pathologies were extrapolated proportionately from 
model outputs. Nevertheless, the results are consistent, showing a dose-effect decline in all 
9vHPV-related pathologies with increasing vaccine coverage in the population. 
 
 
 
 
Table 7. Average annual incidences per hundred thousand population for 9vHPV-related 
diseases across three HPV-MOK simulation scenarios of Kentucky’s next 66 years. 
Diseases S1: incidence rates S2: incidence rates S3: incidence rates 
Cervical Pre-cancers 
     CIN1 
     CIN2 
     CIN3 
 
290.00 
122.98 
23.55 
 
82.82 
37.04 
7.45 
 
27.86 
14.39 
3.22 
Cancers 
     Cervical      
     Oropharyngeal 
     Anogenital 
     Vaginal 
     Vulvar 
     Penile 
 
15.03 
8.78 
2.28 
1.39 
6.36 
1.14 
 
10.94 
6.39 
1.66 
1.01 
4.63 
0.83 
 
8.76 
5.12 
1.33 
0.81 
3.71 
0.66 
Condylomas 194.50 25.93 12.83 
JORRP 0.88 0.16 0.08 
 
 
 
 
 
 Deaths attributable to the 9vHPV types, which were calculated as a proportion of cervical 
cancer mortality rates, declined over time following introduction of the 9-valent vaccine in 
scenarios 2 and 3 (Figure 4 and Table 8). The required vaccination policy in Scenario 3 nearly 
eliminated 9vHPV-related deaths within the lifetime of the first policy cohort (Figure 4-c). 
 
 
 31 
 
Figure 4. 9vHPV-related mortality among scenarios 1 – no vaccination (a), 2 – current vaccination 
rates (b), and 3 – required vaccination under proposed policy (c). 
 
 
 
 
 
 
 
 
Table 8. Annual averages per hundred thousand population for 9vHPV-related mortality across 
three HPV-MOK simulation scenarios of Kentucky’s next 66 years. 
Diseases S1: mortality rates S2: mortality rates S3: mortality rates 
Cancers 
     Cervical      
     Oropharyngeal 
     Anogenital 
     Vaginal 
     Vulvar 
     Penile 
 
2.88 
1.98 
0.19 
0.22 
0.38 
0.11 
 
2.10 
1.44 
0.14 
0.16 
0.28 
0.08 
 
1.68 
1.15 
0.11 
0.13 
0.22 
0.07 
 
 
a 
b 
c 
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Aim 2: Health Impact 
From disease-specific mortality rates, life-years and QALYs lost were calculated. When 
compared to the pre-vaccine conditions of Scenario 1, both vaccine scenarios showed an inverse 
linear relationship between vaccine coverage and cancer deaths (Figure 4), and a positive linear 
relationship of coverage with both life years (Figure 5) and QALYs gained (Figure 6). As 
expected, Scenario 3’s higher vaccination rate produced the greater slope, though the model’s 
dramatic herd effect reduced the proportional rate of return for vaccination overall. On average 
annually, Scenario 1 lost 55.4 life years per 100 thousand population to 9vHPV-related cancers; 
Scenario 2 lost 47.5, and Scenario 3 lost 42.4 life years per 100 thousand. A more dramatic ratio 
was observed for QALYs lost, with Scenario 1 losing an average of 87.4 QALYs per 100 
thousand population to 9vHPV-related diseases annually, compared to 61.8 and 51.4 in 
Scenarios 2 and 3, respectively. 
 
 
 
 
Figure 5. Annual life-years gained per 100k population over 66 years in two 9vHPV vaccination 
scenarios vs. no vaccination. 
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Figure 6. Annual QALYs gained per 100k population over 66 years in two 9vHPV vaccination 
scenarios vs. no vaccination. 
 
 
 
Aim 3: Economic Impact 
 Figure 7 shows the total annual economic costs per hundred thousand population for 
prevention, screening, and treatment of diseases associated with 9 types of HPV, at current value 
after discounting and adjusting for general inflation. Scenario 1 predicted an annual screening 
and treatment cost range of 5.1m to 12.4m (8.4m average) USD per hundred thousand over the 
next 66 years, vs. the 4.5m to 7.5m (5.8m average) predicted by Scenario 2, and the 4.4m to 
7.2m (5.4m average) predicted by Scenario 3 (Table 9), which both include the additional costs 
associated with the HPV vaccine. Total costs remained close during the first 20 years of 
simulations, with a dramatic annual savings attributable to vaccination emerging and growing 
after that. 
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Figure 7. Total discounted costs per 100k population for prevention, screening, and treatment of 
9vHPV-related diseases over 66 years among scenarios 1 – no vaccination, 2 – current 
vaccination rates, and 3 – required vaccination under proposed policy. 
 
 
 
 
 
Table 9. HPV-MOK breakdown of annual averages per hundred thousand population for 9vHPV-
related costs across three scenarios of Kentucky’s next 66 years. 
Expenditures S1: costs (PV; USD) S2: costs (PV; USD) S3: costs (PV; USD) 
Vaccination N/A 212,892 696,718 
Screening  3,123,826 3,123,826 3,123,826 
Treatment 5,279,080 2,463,323 1,611,607 
Totals: 8,402,906 5,800,041 5,432,151 
 
PV: present value. USD: United States dollars. 
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DISCUSSION 
 Using a stochastic, susceptible-infectious-susceptible (SIS), agent-based dynamic model, 
the long-term health and economic impacts of legislation adding the 9vHPV vaccination to the 
6th grade school entry schedule for both boys and girls in the state of Kentucky was estimated. 
The model simulated the transmission dynamics of 9 HPV types, and the pathological 
progression of related cervical disease. Model outputs were aggregated, extended to account for 
other HPV-related pathologies, and analyzed to determine such legislation’s health effects and 
cost-effectiveness. 
Major Findings 
Given base assumptions of stable screening rates, stable healthcare and general economic 
inflation, stable population growth, exclusive use of the 9vHPV vaccine and stable vaccine costs, 
100% vaccine efficacy, and a discount rate of 3.0% applied to economic and health impact 
measures, Scenario 1, which represented the state of Kentucky from the pre-vaccine era, 
predicted a total of approximately 118 thousand 9vHPV-related cancers and 19.5 thousand 
subsequent deaths, together costing 180 thousand life-years, 283 thousand quality-adjusted life-
years, and 28.6 billion USD in direct healthcare utilization in the state of Kentucky over 66 
years.  
Scenario 2, based on current vaccination coverage in the state, predicted fewer total 
cancers (83.6 thousand), cancer deaths (13.8 thousand), life-years lost (151 thousand), QALYs 
lost (195 thousand), and reduced direct costs (19.4 billion USD) over the next 66 years, giving us 
a picture of what might be expected from the real-world status quo.  
Scenario 3, representing Kentucky after passage of legislation similar to 13RS-HB358, 
and using an estimated vaccine uptake rate of 83.125%, predicted still fewer 9vHPV-related 
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cancers, deaths, life-years and QALYs lost, and lower direct costs than Scenarios 1 and 2 (Table 
10).   
 
 
 
Table 10. HPV-MOK cumulative HPV-related disease outcomes and costs across three 
vaccination scenarios of Kentucky’s next 66 years under base assumptions. 
 S1: No Vaccination S2: Current Vaccination S3: Required Vaccination 
Cancers 118,104 83,560 65,607 
Deaths 19,452 13,763 10,806 
Life-years lost (PV) 179,699 151,251 133,299 
QALYs lost (PV) 282,675 195,378 160,706 
Costs (PV; USD) 28.615b 19.439b 18.144b 
 
PV: present value. USD: United States dollars. 
 
 
HPV-MOK predicted that uptake of the 9vHPV vaccine at current levels (as in Scenario 
2) will, over 66 years, prevent 34.5 thousand cancers, save nearly 6 thousand lives, preserve 28 
thousand life years and 87 thousand QALYs, and save 9.176 billion USD in healthcare 
expenditures that would have occurred in Kentucky over 66 years had the vaccine not been 
developed or adopted. This large effect is out of proportion to the scale of direct vaccine 
coverage in Scenario 2, indicating a large herd effect predicted by the model’s transmission 
algorithms that may not reflect real-world dynamics and outcomes.  
When simulating higher vaccination rates consistent with what could be expected from 
passage of legislation requiring the 9vHPV vaccine for school entry in Kentucky, HPV-MOK 
predicts the prevention of a total of 52.5 thousand cancers and nearly 9 thousand deaths, saving 
46 thousand life-years, 122 thousand QALYs, and 10.470 billion USD that would have been lost 
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without the vaccine (Table 11). But neither of these comparisons tells us what effect a policy like 
13RS-HB358 could have in the real post-vaccine world of Kentucky in 2018. 
Looking forward over 66 years along 2 diverging paths, one representing policy inaction 
and stagnant vaccine uptake growth, the other legislative action adding the 9vHPV vaccine to the 
school entry schedule for all 6th graders in the state, the latter could see Kentucky prevent 18 
thousand cancers and 3 thousand deaths, saving nearly 18 thousand life years, 35 thousand 
QALYs, and 1.294 billion USD, for an estimated ICER per QALY of negative 37 thousand USD 
over the former path of policy inaction (Table 11). From this, we conclude that a bill like 13RS-
HB35 would not only be cost-effective in Kentucky, but could be cost-saving. This is likely 
attributable to 1) Kentucky’s high HPV prevalence and high HPV-related disease burden, 2) the 
state’s currently low rates of HPV vaccination, especially among boys, 3) this study’s 
comprehensive inclusion of all direct 9vHPV-related costs and effects, and 4) the savings 
realized from fewer required vaccine doses (from 3 to 2 doses per most recent guidelines).  
 
 
Table 11. Vaccine impact: vaccine era vs. pre-vaccine era under base assumptions. 
 S1:S2 Current gains over  
pre-vaccine era 
S1:S3 Potential policy gains  
over pre-vaccine era 
S2:S3 Policy Impact over  
current vaccination rates 
Cancers prevented 34,544 52,497 17,953 
Lives saved 5,690 8,647 2,957 
Life-years gained (PV) 28,449 46,400 17,952 
QALYs gained (PV) 87,296 121,969 34,672 
Savings (PV; USD) 9.176b 10.470b 1.294b 
ICER (PV; USD) -105,114 -85,845 -37,330 
 
PV: present value. USD: United States dollars. 
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Sensitivity Analysis 
The sensitivity of the model’s predictions to discount rate and time horizon was explored, 
per expert consensus.89 Table 12 shows that, even though outcome and impact benefits are 
heavily weighted to the far future, and even though Scenario 2 produced a much larger herd 
immunity effect than expected, which reduced the measured impact of Scenario 3 by 
comparison, ICERs per QALY in the policy scenario remained well below the 50,000 USD 
threshold for utility even with the most unfavorable tested values for vaccine cost, time horizon, 
and discount rate. Thus the conclusion of cost-effectiveness is robust despite the model’s 
sensitivity to discounting, discount rate, vaccine pricing and dosing, and time horizon. 
 
 
 
Table 12. HPV-MOK policy impact: sensitivity to discounting, discount rate, dosing, and time 
horizon, S2:S3. 
Impact measures  
At time horizons; PV 
Discount Rates 
1.5%* 1.5% 3.0% 5.0% 10.0% 
66-years 
     QALYs gained 
     Cost (USD) 
          3-dose cost (USD) 
     ICER (USD) 
          3-dose ICER (USD) 
 
107,025 
-2.6b 
-1.1b 
-24,155 
-10,254 
 
58,893 
-2.6b 
-1.1b 
-43,897 
-18,634 
 
34,672† 
-1.3b† 
-0.5b 
-37,330† 
-13,667 
 
19,035 
-0.5b 
-0.1b 
-28,003 
-6,210 
 
6,763 
-65m 
67m 
-9,732 
9,915 
40-years 
     QALYs gained 
     Cost (USD) 
          3-dose cost (USD) 
     ICER (USD) 
          3-dose ICER (USD) 
 
52,259 
-0.9b 
 
-17,411 
 
34,592 
-0.9b 
-0.3b 
-26,303 
-9,436 
 
23,695 
-0.6b 
-0.1b 
-23,579 
-5,991 
 
15,131 
-0.3b 
-14m 
-19,250 
-944 
 
6,433 
-52m 
71m 
-8,126 
11,062 
20-years 
     QALYs gained 
     Cost (USD) 
          3-dose cost (USD) 
     ICER (USD) 
          3-dose ICER (USD) 
 
8,013 
-24m 
 
-3,053 
 
7,222 
-24m 
0.2b 
-3,388 
26,811 
 
6,512 
-20m 
0.2b 
-3,165 
25,414 
 
5,681 
-15m 
0.1b 
-2,585 
24,176 
 
4,065 
~500k 
97m 
119 
23,802 
 
PV: present value. USD: United States dollars. 
*Discounting applied to monetary values only; Life-years and QALYs not discounted. 
†Base case conditions. 
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Limitations 
This study has a number of limitations common to complex simulations. First, none of 
the model’s assumptions hold perfectly with reality. Screening rates, economic terms, natural 
immunity, vaccine efficacy and duration of immunity, and many others are simplifications that 
affect the model’s fidelity in unmeasured ways. Second, because only heterosexual transmission 
was considered, the effects of transmission dynamics and elevated prevalence rates among 
homosexuals were left out of simulations. Third, the model assumes a closed society, though 
globalization and regional economics drive immigration and emigration patterns in Kentucky 
now and likely even more so in the future. Fourth, the model assumes cervical cancer screening 
practices will remain constant into the future, though this is unlikely given the effectiveness of 
the HPV vaccine, especially if there is widespread state-level legislative action in the near term. 
Whatever changes to screening practices may unfold in the future, they are unaccounted for here. 
Fifth, multiple sources originally documenting differing populations and dates were necessarily 
used to compile QALY weights, treatment cost estimations, disease incidences, and type-specific 
prevalences, which can lead to discrepancies and inaccuracies when combined, though all efforts 
were made to minimize such instances. Finally, natural variations in 9vHPV type prevalences 
and related disease incidences that might occur in the future were not considered by the HPV-
MOK, which bounds our findings temporally to policy action in the near-term. Should a policy 
decision be significantly delayed, the accuracy of the current analysis may wane. 
Conclusions 
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Based on the results of this study, Kentucky could prevent cancers, save lives, and save 
money by vaccinating as many 11-year-old boys and girls with the 9vHPV vaccine as possible. 
Given the slow pace of vaccine uptake in the state since 2006, the most effective path toward 
universal vaccination is likely through legislative action at the state level. Despite sensitivity to 
variable variances, the conclusion of cost-effectiveness is robust. Further, through much of the 
variance range, the model predicts overall cost savings from legislation passage. Most 
importantly, the model predicts that HPV vaccine legislation could save many lives and prevent 
a great deal of suffering for present and future generations in the Commonwealth. 
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